Patents by Inventor Hiroki Sasaki

Hiroki Sasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220223825
    Abstract: There are provided: a laminate including a wavelength selective absorption layer containing a resin, a dye containing at least one of four specific dyes A to D, and an antifading agent for a dye and a gas barrier layer directly arranged on at least one surface of the wavelength selective absorption layer, in which the gas barrier layer contains a crystalline resin, has a layer thickness of 0.1 ?m to 10 ?m, and has a layer oxygen permeability of 60 cc/m2·day·atm or less; and an organic electroluminescent display device.
    Type: Application
    Filed: February 22, 2022
    Publication date: July 14, 2022
    Applicant: FUJIFILM Corporation
    Inventors: Hiroki KUWAHARA, Nobutaka FUKAGAWA, Daisuke SASAKI
  • Publication number: 20220087987
    Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 24, 2022
    Applicants: National Cancer Center, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki OGIWARA, Takashi KOHNO, Hiroki SASAKI
  • Publication number: 20210399034
    Abstract: A camera module is configured to capture an optical image of a target area and includes a lens member, an imager, a light transmitting member, and a seat. The lens member is configured to receive light from the target area. The imager has a curved portion convex in a direction away from the lens member and is configured to capture the optical image formed on the curved portion. The light transmitting member optically couples the lens member and the imager. The seat has a supporting portion that supports an outer rim of the imager and a fluid space defined inside the supporting portion. A heat dissipation fluid undergoes convection in the fluid space. The curved portion is interposed between the light transmitting member and the seat having the supporting portion and the fluid space.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 23, 2021
    Inventors: Kouji SATOU, Hiroki SASAKI, Shotaro MIYAWAKI, Akira WADA, Satoru WAKIYAMA, Kazuhiro AOYAMA
  • Publication number: 20210292853
    Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventor: Hiroki SASAKI
  • Patent number: 11053553
    Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 6, 2021
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventor: Hiroki Sasaki
  • Patent number: 10969390
    Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: April 6, 2021
    Assignees: NATIONAL CANCER CENTER, KYOTO UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki Sasaki, Kazuhiko Aoyagi, Manabu Muto, Hiroo Takahashi
  • Patent number: 10903228
    Abstract: A semiconductor storage device includes a semiconductor substrate and a plurality of first wiring layers stacked above the semiconductor substrate in a first direction orthogonal to the semiconductor substrate, and extending in a second direction intersecting the first direction and parallel to the semiconductor substrate. The device further includes a first memory pillar including a semiconductor layer and a first insulation layer extending in the first direction, the first insulation layer provided between the plurality of first wiring layers and the semiconductor layer so as to contact the semiconductor layer, and charge storage layers provided respectively between the plurality of first wiring layers and the first insulation layer. One or more of the charge storage layers is in contact with the first insulation layer. A plurality of second insulation layers is provided between each of the plurality of first wiring layers and each of the charge storage layers.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 26, 2021
    Assignee: TOSHIBA MEMORY CORPORATION
    Inventors: Hiroki Sasaki, Atsushi Murakoshi, Ryuji Ohba
  • Publication number: 20200385779
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.
    Type: Application
    Filed: March 13, 2020
    Publication date: December 10, 2020
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa, Makoto Asaumi, Kazuhisa Tsunoyama
  • Patent number: 10818688
    Abstract: A storage device includes: a plurality of electrode films stacked in a first direction, and extending in a second direction intersecting the first direction; a first semiconductor film provided adjacent to the plurality of electrode films, and extending in the first direction; a first charge holding film provided between one electrode film among the plurality of electrode films, and the semiconductor film, and including any one of a metal, a metal compound, and a high dielectric material; and a second semiconductor film located between the first semiconductor film and the charge holding film, and extending in the first direction along the first semiconductor film. The second semiconductor film is electrically insulated from the plurality of electrode films, the first charge holding film, and the first semiconductor film.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 27, 2020
    Assignee: TOSHIBA MEMORY CORPORATION
    Inventors: Atsushi Murakoshi, Hiroki Sasaki
  • Publication number: 20200299782
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an RP2 gene and a part of an ARHGAP6 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding RP2 and an antisense primer designed from a section encoding ARHGAP6.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 24, 2020
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa
  • Patent number: 10619216
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an RP2 gene and a part of an ARHGAP6 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding RP2 and an antisense primer designed from a section encoding ARHGAP6.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: April 14, 2020
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa
  • Patent number: 10619184
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: April 14, 2020
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa, Makoto Asaumi, Kazuhisa Tsunoyama
  • Publication number: 20190273092
    Abstract: A semiconductor storage device includes a semiconductor substrate and a plurality of first wiring layers stacked above the semiconductor substrate in a first direction orthogonal to the semiconductor substrate, and extending in a second direction intersecting the first direction and parallel to the semiconductor substrate. The device further includes a first memory pillar including a semiconductor layer and a first insulation layer extending in the first direction, the first insulation layer provided between the plurality of first wiring layers and the semiconductor layer so as to contact the semiconductor layer, and charge storage layers provided respectively between the plurality of first wiring layers and the first insulation layer. One or more of the charge storage layers is in contact with the first insulation layer. A plurality of second insulation layers is provided between each of the plurality of first wiring layers and each of the charge storage layers.
    Type: Application
    Filed: August 27, 2018
    Publication date: September 5, 2019
    Applicant: TOSHIBA MEMORY CORPORATION
    Inventors: Hiroki SASAKI, Atsushi MURAKOSHI, Ryuji OHBA
  • Publication number: 20190259774
    Abstract: A storage device includes: a plurality of electrode films stacked in a first direction, and extending in a second direction intersecting the first direction; a first semiconductor film provided adjacent to the plurality of electrode films, and extending in the first direction; a first charge holding film provided between one electrode film among the plurality of electrode films, and the semiconductor film, and including any one of a metal, a metal compound, and a high dielectric material; and a second semiconductor film located between the first semiconductor film and the charge holding film, and extending in the first direction along the first semiconductor film. The second semiconductor film is electrically insulated from the plurality of electrode films, the first charge holding film, and the first semiconductor film.
    Type: Application
    Filed: September 6, 2018
    Publication date: August 22, 2019
    Applicant: TOSHIBA MEMORY CORPORATION
    Inventors: Atsushi MURAKOSHI, Hiroki SASAKI
  • Publication number: 20190218620
    Abstract: The purpose is to reveal a polynucleotide that is a novel causal gene of pancreatic cancer and thereby provide a method for detecting the polynucleotide or a polypeptide encoded thereby to select a subject positive for the polynucleotide or polypeptide and a method expected to be useful for to identify patients suitable for therapies and a primer set therefor and a kit for detection. In the method, a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP6 gene or a polynucleotide comprising a fusion point of a part of a CLDN18 gene and an ARHGAP26 gene, or a fusion protein encoded thereby is detected. The primer set comprises a sense primer designed for a part encoding CLDN18 and an antisense primer designed for a part encoding ARHGAP6 or a part encoding ARHGAP26.
    Type: Application
    Filed: August 9, 2017
    Publication date: July 18, 2019
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventor: Hiroki SASAKI
  • Patent number: 10113907
    Abstract: Provided are an ultraviolet-sensing sheet, an ultraviolet-sensing set, and an ultraviolet-sensing method, in which color gradation properties which are suitable for detecting an ultraviolet dose are obtained and in which the coloring of an ultraviolet-sensing layer caused by the effect of light other than ultraviolet light is prevented. An ultraviolet-sensing sheet 1 includes: a filter layer 10 that selectively allows transmission of light having a specific wavelength; and an ultraviolet-sensing layer 20 that includes a capsule including a color-forming dye and a photooxidant. It is preferable that the filter layer 10 has a maximum value of the transmittance in a wavelength range of 300 nm or longer and shorter than 380 nm.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: October 30, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Masahiro Hatta, Takayuki Matsumoto, Hiroki Sasaki
  • Publication number: 20180251850
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an RP2 gene and a part of an ARHGAP6 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding RP2 and an antisense primer designed from a section encoding ARHGAP6.
    Type: Application
    Filed: August 23, 2016
    Publication date: September 6, 2018
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa
  • Publication number: 20180237862
    Abstract: The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.
    Type: Application
    Filed: August 23, 2016
    Publication date: August 23, 2018
    Inventors: Hiroki Sasaki, Hitoshi Ichikawa, Makoto Asaumi, Kazuhisa Tsunoyama
  • Publication number: 20180208787
    Abstract: Provided are an aqueous pigment dispersion that includes an azo pigment represented by Formula (1) as described in the specification, and/or a tautomer thereof, the azo pigment showing characteristic X-ray diffraction peaks at least at Bragg's angles (2?±0.2°) of 4.8°, 7.2°, 9.7°, 20.0°, 17.3°, 26.0°, and 26.7° in CuK? characteristic X-ray diffraction; a first dispersant; a second dispersant; and water, the aqueous pigment dispersion being obtained via the following Step b. Step b: a step of dispersing an azo pigment represented by Formula (1) and/or a tautomer thereof, a first dispersant, and a second dispersant in water and thereby obtaining an aqueous pigment dispersion.
    Type: Application
    Filed: March 22, 2018
    Publication date: July 26, 2018
    Applicant: FUJIFILM Corporation
    Inventors: Keiichi TATEISHI, Hiroki SASAKI, Yoshiaki NAGATA
  • Publication number: 20170292955
    Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Applicants: NATIONAL CANCER CENTER, KYOTO UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki SASAKI, Kazuhiko AOYAGI, Manabu MUTO, Hiroo TAKAHASHI